Leukemia research · 2004
Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma.
Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Giles Francis J, Vose Julie M, Do Kim-Anh, Johnson Marcella M, Manshouri Taghi, Bociek Gregory, Bierman Philip J, O'Brien Susan M, Kantarjian Hagop M, Armitage James O, Albitar Maher
Аннотация
Vascular endothelial growth factor (VEGF), basic-fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and angiogenin are important angiogenic factors. In 65 patients with non-Hodgkin's lymphoma (NHL), pre-treatment VEGF, bFGF, and HGF levels were significantly elevated compared to normal individuals, while angiogenin levels were significantly subnormal. In 37 patients with Hodgkin's disease, pre-treatment levels of VEGF and HGF were significantly elevated, bFGF levels were normal, and angiogenin levels were significantly subnormal. In patients with NHL, post-therapy levels of angiogenin were independently predictive of survival. Both pre-therapy and post-therapy VEGF levels were independently predictive of survival in patients with HD.
Предметные рубрики MeSH
AdolescentAdultAgedAged, 80 and overFemaleFibroblast Growth Factor 2Hepatocyte Growth FactorHodgkin DiseaseHumansLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMaleMiddle AgedNeoplastic Cells, CirculatingNeovascularization, PathologicPredictive Value of TestsRibonuclease, PancreaticSurvival RateVascular Endothelial Growth Factor A